---
layout: post
title: New Drug Approvals 2012 - Pt. XXIV - Ocriplasmin (JetreaTM)
date: '2012-11-09T07:03:00.000Z'
author: Patricia
tags:
- Parenteral Drugs
- Enzyme drugs
- 2012 New Drugs
modified_time: '2012-11-09T07:03:32.306Z'
thumbnail: http://1.bp.blogspot.com/-R1WVN6jBl48/UJkk0GbXORI/AAAAAAAAAsc/lxc6XBY7p2o/s72-c/jetrea_logo.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-5007510861488924704
blogger_orig_url: http://chembl.blogspot.com/2012/11/new-drug-approvals-2012-pt-xxiv.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-R1WVN6jBl48/UJkk0GbXORI/AAAAAAAAAsc/lxc6XBY7p2o/s1600/jetrea_logo.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="111" src="http://1.bp.blogspot.com/-R1WVN6jBl48/UJkk0GbXORI/AAAAAAAAAsc/lxc6XBY7p2o/s320/jetrea_logo.png" width="320" /></a></div>
<br />
<center>
</center>
<center>
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/2,0,0,0,1,0,0,0,0" width="400" /><br />
</center>
<br />
<div style="text-align: left;">
On October 17, the FDA approved Ocriplasmin (tradename: <a href="http://www.trademarkia.com/jetrea-85722768.html">Jetrea</a>; Research Code: Microplasmin), a <a href="http://en.wikipedia.org/wiki/Protease">proteolytic enzyme</a> indicated for the treatment of symptomatic <a href="http://en.wikipedia.org/wiki/Vitreomacular_adhesion">vitreomacular adhesion (VMA)</a>. VMA is a condition of the eye that results from the liquefaction of the <a href="http://en.wikipedia.org/wiki/Vitreous_humour">vitreous gel</a> within the human eye and consequent adhesion to the <a href="http://en.wikipedia.org/wiki/Retina">retina</a>. As the eye ages, the vitreous humor can naturally separate from the retina. However, if the separation is not complete, areas of adhesion can occur. The traction from these adhesion areas on the retinal surface is the underlying pathology of symptomatic VMA, which can lead to ocular damage. Ocriplasmin is the first drug approved to treat this condition and it exherts its therapeutic action by selectively breaking down the three major protein components, <a href="http://en.wikipedia.org/wiki/Fibronectin">fibronectin</a>, <a href="http://en.wikipedia.org/wiki/Laminin">laminin</a> and <a href="http://en.wikipedia.org/wiki/Collagen">collagen</a>, of the vitreous body and vitreoretinal interface, and thereby dissolving the protein matrix responsible for VMA. The only alternative treatment is a surgical procedure to remove the vitreous from the eye, known as vitrectomy.<br />
<br />
Ocriplasmin is a recombinant truncated form of the human plasmin (ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL1801">CHEMBL1801</a>; Uniprot: <a href="http://www.uniprot.org/uniprot/P00747">P00747</a>) with a molecular weight of 27.2 kDa produced by recombinat DNA technology in a <i>Pichia pastoris</i> expression system.<br />
<br /></div>
<div style="font-family: &quot;Courier New&quot;,Courier,monospace; text-align: left;">
&gt;PLMN_HUMAN Plasminogen (Ocriplasmin is displayed in bold)<br />
MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT<br />
CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN<br />
GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE<br />
CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE<br />
LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS<br />
AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE<br />
QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG<br />
LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED<br />
CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG<br />
PWCYTTNPRKLYDYCDVPQCA<b>APSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT<br />
RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE<br />
PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ<br />
LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW<br />
GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</b><br />
<br /></div>
The PDBe entry (<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/1bui/summary">PDBe:1bui</a>) for the crystal structure of Ocriplasmin (in green) in complex with Staphylokinase (in red) is displayed below.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-ZYQwYphNXl0/UJkqy0dLaDI/AAAAAAAAAsw/_m6gzjzn3ZU/s1600/full3.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="300" src="http://2.bp.blogspot.com/-ZYQwYphNXl0/UJkqy0dLaDI/AAAAAAAAAsw/_m6gzjzn3ZU/s400/full3.png" width="400" /></a></div>
<br />
The recommended dosage of Ocriplasmin is 0.125 mg (0.1 mL of the diluted solution) administrated by intravitreal injection to the affected eye once as a single dose.<br />
<br />
The license holder is <a href="http://thrombogenics.com//">ThromboGenics, Inc.</a> and the full prescribing information of Linaclotide can be found <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125422s000lbl.pdf">here</a>.